Supplementing obese zucker rats with niacin induces the transition of glycolytic to oxidativeskeletal muscle fibers

Journal of Nutrition

Volumn 143, Issue 2, 2013, Pages 125-131

  Ringsei, Robert ^a   Rosenbaum, Susann ^a   Gessner, Denise K ^a   Herges, Lea ^a   Kubens, Johanna F ^a   Mooren, Frank Christoph ^a   Krüger, Karsten ^a   Eder, Klaus ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COX4I1 PROTEIN; COX6A2 PROTEIN; CPT1B PROTEIN; FATTY ACID; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PPARD PROTEIN; PROTEIN; SLC22A4 PROTEIN; SLC22A5 PROTEIN; SLC25A20 PROTEIN; SLC27A1 PROTEIN; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOGENESIS; BLOOD LEVEL; CELL COMPOSITION; CONTROLLED STUDY; INSULIN RESISTANCE; MALE; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXYGEN AFFINITY; OXYGEN CONSUMPTION; PHENOTYPE; RAT; SKELETAL MUSCLE; UPREGULATION; ZUCKER RAT;

ANIMALS; DIETARY SUPPLEMENTS; GENE EXPRESSION REGULATION; GLYCOLYSIS; HYPOLIPIDEMIC AGENTS; LIPID MOBILIZATION; LIVER; MALE; MITOCHONDRIAL TURNOVER; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE PROTEINS; NIACIN; OBESITY; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, ZUCKER; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84873050820     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.112.164038     Document Type: Article

References (42)

1. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-17.
2. Goldberg RB. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes. Am J Manag Care. 2000;6:S682-91.
3. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79-106.
4. Karpe F, Frayn KN. The nicotinic acid receptor: a new mechanism for an old drug. Lancet. 2004;363:1892-4.
5. Wang W, Basinger A, Neese RA, Shane B, Myong SA, Christiansen M, Hellerstein MK. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab. 2001;280:E540-7.
6. Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, IJzerman AP. International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev. 2011;63:269-90.
7. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303:364-9.
8. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplweski K, Green A, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278:9869-74.
9. Choi S, Yoon H, Oh KS, Oh YT, Kim YI, Kang I, Youn JH. Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment. Metabolism. 2011;60:134-44.
10. WattMJ, Southgate RJ, Holmes AG, Febbraio MA. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) a and d and PPAR coactivator 1a in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol. 2004;33:533-44.
11. Barish GD, Narkar VA, Evans RM. PPARd: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-7.
12. Lin JD. Minireview: the PGC-1 coactivator networks: chromatinremodeling and mitochondrial energy metabolism. Mol Endocrinol. 2009;23:2-10.
13. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARd. PLoS Biol. 2004;2:e294.
14. Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, Metzger D. PGC1a expression is controlled in skeletal muscles by PPAR b, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006;4: 407-14.
15. Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, Sawada N, Raghuram S, Arany Z. The transcriptional coactivator PGC- 1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci USA. 2009;106:21401-6.
16. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA. Peroxisome proliferator-activated receptor d controls muscle development and oxidative capability. FASEB J. 2003;17:2299-301.
17. Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, Meier CA, Bell DR, Kralli A, Giacobino JP, et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-g coactivator-1 and peroxisome proliferatoractivated receptor a in skeletal muscle. Diabetes. 2003;52:2874-81.
18. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, van Meeteren LA, Samen E, Lu L, Vanwildemeersch M, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature. 2010;464:917-21.
19. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
20. Hämäläinen N, Pette D. The histochemical profiles of fast fiber types IIB, IID, and IIA in skeletal muscles of mouse, rat, and rabbit. J Histochem Cytochem. 1993;41:733-43.
21. Ringseis R, Muschick A, Eder K. Dietary oxidized fat prevents ethanolinduced triacylglycerol accumulation and increases expression of PPARa target genes in rat liver. J Nutr. 2007;137:77-83.
22. Keller J, Ringseis R, Koc A, Lukas I, Kluge H, Eder K. Supplementation with l-carnitine downregulates genes of the ubiquitin proteasome system in the skeletal muscle and liver of piglets. Animal. 2012;6:70-8.
23. Ringseis R, Mooren FC, Keller J, Couturier A, Wen G, Hirche F, Stangl GI, Eder K, Krüger K. Regular endurance exercise improves the diminished hepatic carnitine status in mice fed a high-fat diet. Mol Nutr Food Res. 2011;55 Suppl 2:S193-202.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
25. Rosen H, Rakita RM, Waltersdorph AM, Klebanoff SJ. Myeloperoxidasemediated damage to the succinate oxidase system of Escherichia coli. Evidence for selective inactivation of the dehydrogenase component. J Biol Chem. 1987;262:15004-10.
26. Guyton JR. Effect of niacin on cardiovascular disease. Am J Cardiol. 1998;82:U18-23.
27. Gallo M, MacLean I, Tyreman N, Martins KJB, Syrotuik D, Gordon T, Putman CT. Adaptive responses to creatine loading and exercise in fasttwitch rat skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1319-28.
28. Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008;18:426-34.
29. Arany Z, Lebrasseur N, Morris C, Smith E, Yang W, Ma Y, Chin S, Spiegelman BM. The transcriptional coactivator PGC-1b drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 2007;5:35-46.
30. Mortensen OH, Frandsen L, Schjerling P, Nishimura E, Grunnet N. PGC-1a and PGC-1b have both similar and distinct effects on myofiber switching toward an oxidative phenotype. Am J Physiol Endocrinol Metab. 2006;291:E807-16.
31. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, et al. Ablation of PGC-1b results in defective mitochondrial activity, thermogenesis, hepatic function, cardiac performance. PLoS Biol. 2006;4:e369.
32. Pereira JN. The plasma free fatty acid rebound induced by nicotinic acid. J Lipid Res. 1967;8:239-44.
33. Wang W, Basinger A, Neese RA, Christiansen M, Hellerstein MK. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab. 2000;279:E50-9.
34. O'Neill M, Watt MJ, Heigenhauser GJ, Spriet LL. Effects of reduced free fatty acid availability on hormone-sensitive lipase activity in human skeletal muscle during aerobic exercise. J Appl Physiol. 2004;97:1938-45.
35. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism. 2003;52:699-704.
36. Rasouli N, Hale T, Kahn SE, Spencer HJ, Elbein SC. Effects of shortterm experimental insulin resistance and family history of diabetes on pancreatic b-cell function in nondiabetic individuals. J Clin Endocrinol Metab. 2005;90:5825-33.
37. Oh YT, Oh KS, Choi YM, Jokiaho A, Donovan C, Choi S, Kang I, Youn JH. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am J Physiol Endocrinol Metab. 2011;300:E1012-21.
38. Quabbe HJ, Luyckx AS, L'age M, Schwarz C. Growth hormone, cortisol, and glucagon concentrations during plasma free fatty acid depression: different effects of nicotinic acid and an adenosine derivative (BM 11.189). J Clin Endocrinol Metab. 1983;57:410-4.
39. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007;193:361-5.
40. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism. 2008;57:404-9.
41. Le Bloc'h J, Leray V, Chetiveaux M, Freuchet B, Magot T, Krempf M, Nguyen P, Ouguerram K. Nicotinic acid decreases apolipoprotein B100- containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J Pharmacol Exp Ther. 2010;334:583-9.
42. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004;45:1835-45.